Up to 90% of neuroendocrine tumor patients have metastatic disease in the liver at diagnosis. These patients are treated with somatostatin analog therapy and monitored with CT or MRI. We demonstrate in a retrospective study that somatostatin therapy is associated with the development of elevated liver fat fraction on MRI. Furthermore, preliminary results suggest that hepatic steatosis decreases lesion detectability on CT compared to MRI. Studies are ongoing to determine the severity of steatosis and relationship to cumulative somatostatin dose, variation in fat fraction over time and the response to change in medication, and effect on liver function.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords